282 related articles for article (PubMed ID: 29718756)
1. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
[TBL] [Abstract][Full Text] [Related]
2. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis.
Al Sawah S; Foster SA; Goldblum OM; Malatestinic WN; Zhu B; Shi N; Song X; Feldman SR
J Med Econ; 2017 Sep; 20(9):982-990. PubMed ID: 28635342
[TBL] [Abstract][Full Text] [Related]
3. Comorbidity and economic burden among moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population.
Lee S; Xie L; Wang Y; Vaidya N; Baser O
J Med Econ; 2018 Jun; 21(6):564-570. PubMed ID: 29359606
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity.
Murage MJ; Anderson A; Casso D; Oliveria SA; Ojeh CK; Muram TM; Merola JF; Zbrozek A; Araujo AB
J Dermatolog Treat; 2019 Mar; 30(2):141-149. PubMed ID: 29799292
[TBL] [Abstract][Full Text] [Related]
6. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
Seetasith A; Greene M; Hartry A; Burudpakdee C
J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population.
Rice JB; White AG; Johnson M; Wagh A; Qin Y; Bartels-Peculis L; Ciepielewska G; Nelson WW
J Med Econ; 2018 Sep; 21(9):846-852. PubMed ID: 29741439
[TBL] [Abstract][Full Text] [Related]
8. Real-World Claims Analyses of Comorbidity Burden, Treatment Pattern, Healthcare Resource Utilization, and Costs in Pediatric Psoriasis.
Edson-Heredia E; Anderson S; Guo J; Zhu B; Malatestinic WN; Wine-Lee L; Swanson E
Adv Ther; 2021 Jul; 38(7):3948-3961. PubMed ID: 34091866
[TBL] [Abstract][Full Text] [Related]
9. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
[TBL] [Abstract][Full Text] [Related]
10. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis.
Feldman SR; Zhao Y; Shi L; Tran MH
J Manag Care Spec Pharm; 2015 Oct; 21(10):874-88. PubMed ID: 26402388
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
Samuelsen C; Lim J; Golembesky A; Shrestha S; Wang L; Griebsch I
J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
[No Abstract] [Full Text] [Related]
12. Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis.
Trantham L; Sikirica MV; Candrilli SD; Benson VS; Mohan D; Neil D; Joshi AV
J Med Econ; 2019 Apr; 22(4):319-327. PubMed ID: 30580639
[TBL] [Abstract][Full Text] [Related]
13. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
Shahabi A; Shafrin J; Zhao L; Green S; Curtice T; Marshall A; Paul D
J Med Econ; 2019 Apr; 22(4):350-358. PubMed ID: 30653389
[TBL] [Abstract][Full Text] [Related]
14. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population.
Lee S; Xie L; Wang Y; Vaidya N; Baser O
J Manag Care Spec Pharm; 2018 Jul; 24(7):654-663. PubMed ID: 29952710
[TBL] [Abstract][Full Text] [Related]
16. Rethinking costs of psoriasis: 10% of patients account for nearly 40% of healthcare expenditures among enrollees with psoriasis in a U.S. health plan.
Armstrong AW; Zhao Y; Herrera V; Li Y; Bancroft T; Hull M; Altan A
J Dermatolog Treat; 2017 Nov; 28(7):613-622. PubMed ID: 28320213
[TBL] [Abstract][Full Text] [Related]
17. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G
J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294
[TBL] [Abstract][Full Text] [Related]
18. Healthcare resource utilization and direct medical costs associated with index and recurrent
Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
[No Abstract] [Full Text] [Related]
19. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Bhowmik D; Hines DM; Intorcia M; Wade RL
J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
